These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 10453966)
41. Testosterone replacement therapy in prostate cancer patients: is it safe? Umbas R; Sugiono M Acta Med Indones; 2010 Jul; 42(3):171-5. PubMed ID: 20724773 [TBL] [Abstract][Full Text] [Related]
42. The aging male: androgens, erectile dysfunction, and depression. Seidman SN J Clin Psychiatry; 2003; 64 Suppl 10():31-7. PubMed ID: 12971814 [TBL] [Abstract][Full Text] [Related]
43. Male menopause: is it a real clinical syndrome? Pines A Climacteric; 2011 Feb; 14(1):15-7. PubMed ID: 20670200 [TBL] [Abstract][Full Text] [Related]
44. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
45. Age-associated testosterone decline in men: clinical issues for psychiatry. Sternbach H Am J Psychiatry; 1998 Oct; 155(10):1310-8. PubMed ID: 9766760 [TBL] [Abstract][Full Text] [Related]
47. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886 [TBL] [Abstract][Full Text] [Related]
48. Normative hypogonadism and depression: Does 'andropause' exist? Seidman SN Int J Impot Res; 2006; 18(5):415-22. PubMed ID: 16395322 [TBL] [Abstract][Full Text] [Related]
49. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Wallis CJ; Lo K; Lee Y; Krakowsky Y; Garbens A; Satkunasivam R; Herschorn S; Kodama RT; Cheung P; Narod SA; Nam RK Lancet Diabetes Endocrinol; 2016 Jun; 4(6):498-506. PubMed ID: 27165609 [TBL] [Abstract][Full Text] [Related]
50. Male Sexual Dysfunction and Hypogonadism Guidelines for the Aging Male. Ahmed K; Hatzimouratidis K; Muneer A Eur Urol Focus; 2017 Oct; 3(4-5):514-516. PubMed ID: 29331623 [TBL] [Abstract][Full Text] [Related]
51. Physiological and clinical characteristics of andropause. Delev DP; Kostadinova II; Kostadinov ID; Ubenova DK Folia Med (Plovdiv); 2009; 51(1):15-22. PubMed ID: 19437894 [TBL] [Abstract][Full Text] [Related]
52. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism. Gray H; Seltzer J; Talbert RL Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507 [TBL] [Abstract][Full Text] [Related]
53. [Testosterone replacement therapy for hypogonadism in men with prostate cancer]. Jensen CF; Fode M; Østergren P; Sønksen J Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152 [TBL] [Abstract][Full Text] [Related]
54. [Testosterone replacement therapy and prostate cancer: the downfall of a paradigm?]. Castillo OA; López-Fontana G; Vidal-Mora I; López Laur JD Medwave; 2015 Apr; 15(3):e6115. PubMed ID: 25919660 [TBL] [Abstract][Full Text] [Related]
55. Testosterone supplementation therapy as a treatment of hypogonadism. Schmidtova E; Kelemenova S; Ostatnikova D Bratisl Lek Listy; 2009; 110(12):765-72. PubMed ID: 20196470 [TBL] [Abstract][Full Text] [Related]
56. Andropause: an androgen deficiency state in the ageing male. Demers LM Expert Opin Pharmacother; 2003 Feb; 4(2):183-90. PubMed ID: 12562308 [TBL] [Abstract][Full Text] [Related]
57. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Thompson CA; Shanafelt TD; Loprinzi CL Oncologist; 2003; 8(5):474-87. PubMed ID: 14530501 [TBL] [Abstract][Full Text] [Related]
58. Partial androgen deficiency and neuropsychiatric symptoms in aging men. Amore M J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):49-54. PubMed ID: 16760626 [TBL] [Abstract][Full Text] [Related]
59. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Rhoden EL; Morgentaler A Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827 [TBL] [Abstract][Full Text] [Related]